Price movement over the last 24 hours
Alcon AG vs Tyson Foods, Inc. — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while Tyson Foods, Inc. trades at $58.65 (market cap $20.71B). The key difference: Alcon AG is the larger of the two by market cap, and Tyson Foods, Inc. pays the higher dividend (3.47%). Which is the better fit depends on your goals.
| ALC | TSN | |
|---|---|---|
Market Cap | $32.69B | $20.71B |
Sector | Health | Consumer Staples |
52-Week High | $92.22 | $68.75 |
52-Week Low | $62.02 | $50.72 |
Enterprise Value | $36.28B | $28.30B |
Dividend Yield | 0.54% | 3.47% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Tyson Foods (TSN) trades at $58.82, down 0.12% on the day, with a bearish technical signal and neutral oscillators. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results pending. Revenue for 2025 was $54.44 billion, with a net income margin of 0.81%. Recent news highlights innovation in prepared foods and new product launches, while analyst consensus is a Buy with a $69.75 price target.
The outlook for TSN is cautiously optimistic, supported by analyst bullishness and strategic growth in value-added products. Key opportunities include strong free cash flow guidance and debt reduction. Risks involve volatile cattle prices, inflationary pressures, and competitive market dynamics. The stock presents a potential upside from current levels, contingent on execution of long-term growth strategies and market conditions.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →